Excess Sudden Cardiac Deaths after Short-Term Clarithromycin Administration in the CLARICOR Trial: Why Is This So, and Why Are Statins Protective?

@article{Winkel2011ExcessSC,
  title={Excess Sudden Cardiac Deaths after Short-Term Clarithromycin Administration in the CLARICOR Trial: Why Is This So, and Why Are Statins Protective?},
  author={P. Winkel and J. Hilden and J. Fischer Hansen and P. Hildebrandt and J. Kastrup and H. J. Kolmos and E. Kj{\o}ller and C. Jespersen and C. Gluud and G. Jensen},
  journal={Cardiology},
  year={2011},
  volume={118},
  pages={63 - 67}
}
Objectives: To elucidate potential mechanisms for the clarithromycin-induced excess mortality observed in the CLARICOR trial during 2.6 year follow-up of patients with stable coronary artery disease. Methods: Cox analyses using out-of-hospital death as a proxy for sudden death compared to in-hospital (nonsudden) death. Result: In 100 of 189 (53%) cardiovascular (CV) deaths in which it was possible to examine the question, there was a strong association between place of death and the… Expand
33 Citations

Paper Mentions

Interventional Clinical Trial
A growing body of evidence links Chlamydia pneumoniae to the progression of coronary heart disease. The purpose of this study is to determine the positive and negative effect of 14… Expand
ConditionsCardiovascular Disease, Heart Disease
InterventionDrug
Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial
  • 19
Macrolides use and the risk of sudden cardiac death
  • 2
...
1
2
3
4
...

References

SHOWING 1-10 OF 16 REFERENCES
Arrhythmic and sudden death in chronic ischemic heart disease--a review of epidemiological data.
  • 8
Antimicrobial-associated QT interval prolongation: pointes of interest.
  • R. Owens, T. Nolin
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
  • 174
  • PDF
...
1
2
...